CSMall Group Limited
金貓銀貓集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1815)

PROFIT WARNING

This announcement is made by CSMall Group Limited (the "**Company**", and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company and potential investors that, based on the Group's unaudited consolidated management accounts for the year ended 31 December 2020 ("**FY2020**") (which have not been confirmed, reviewed or audited by the Company's auditors or audit committee, and may be subject to adjustment) and other information currently available to the Group, the Group expects to record a net loss attributable to owners of the Company of RMB35 million to RMB50 million for FY2020, as compared to a net loss attributable to owners of the Company of approximately RMB5 million for the year ended 31 December 2019. Such expected increase in net loss is mainly attributable to the following factors:

(i) the significant decline in the Group's volume of sales through both its online sales channels and its offline sales and service network during FY2020, as a result of the temporary business suspension due to the COVID-19 outbreak in the first half of FY2020 and the continuously weak consumer sentiment in China throughout the whole FY2020;

(ii) the one-off net loss of RMB25 million to RMB30 million on termination of assignment contract in relation to the acquisition of a land use right, in respect of which approximately RMB27 million was recorded in the first half of FY2020; and

(iii) the one-off net loss of RMB12 million to RMB15 million on inventory write-off upon expiry in relation to the pilot expansion into a new business of COVID-19 diagnostic kit distribution in collaboration with a pharmaceutical company in China.

The Company is still in the process of finalizing its annual results for FY2020. Detailed financial information and performance of the Group for FY2020 will be disclosed in the Company's annual results announcement for FY2020 which is expected to be published by the end of March 2021.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
CSMall Group Limited
Chen He
Chairman

Hong Kong, 15 March 2021

As at the date of this announcement, the executive directors of the Company are Mr. Chen He and Mr. Qian Pengcheng; and the independent non-executive directors of the Company are Mr. Fu Lui, Mr. Hu Qilin and Mr. Zhang Zuhui.